Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,708,963 papers from all fields of science
Search
Sign In
Create Free Account
ABT 888
Known as:
ABT-888
, ABT888
, PARP-1 inhibitor ABT-888
A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
veliparib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC).
S. Pahuja
,
J. Beumer
,
+12 authors
S. Puhalla
2015
Corpus ID: 78213290
1015 Background: Veliparib (ABT-888) is an oral, potent small molecule inhibitor of poly-ADP-ribose polymerase (PARP). The…
Expand
2013
2013
Design, synthesis and biological evaluation of novel imidazo[4,5-c]pyridinecarboxamide derivatives as PARP-1 inhibitors.
Qihua Zhu
,
Xuyan Wang
,
Zhaoxing Chu
,
Guangwei He
,
Guangping Dong
,
Yungen Xu
Bioorganic & Medicinal Chemistry Letters
2013
Corpus ID: 10104796
2013
2013
Poly(ADP-ribose) polymerase 1 inhibition protects against low shear stress induced inflammation.
Weidong Qin
,
Shujian Wei
,
+7 authors
Ming-Xiang Zhang
Biochimica et Biophysica Acta
2013
Corpus ID: 8392945
2012
2012
A phase I study of chronically dosed, single-agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer…
S. L. Huggins-Puhalla
,
J. Beumer
,
+15 authors
E. Chu
2012
Corpus ID: 78680575
3054 Background: Veliparib (ABT-888) is an oral, potent inhibitor of PARP 1/2. Preclinically, PARP inhibitors have activity in…
Expand
Highly Cited
2011
Highly Cited
2011
Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
J. Ji
,
R. Kinders
,
+5 authors
J. Doroshow
PLoS ONE
2011
Corpus ID: 5912237
Background Poly(ADP-ribose) polymerase (PARP)facilitates DNA repair and PARP inhibitors may potentiate the effect of DNA-damaging…
Expand
2011
2011
Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.
Antoinette R. Tan
,
Deborah Toppmeyer
,
+9 authors
R. DiPaola
Journal of Clinical Oncology
2011
Corpus ID: 13552359
3041 Background: Veliparib is a potent, oral inhibitor of PARP-1 and PARP-2. We previously reported phase I results of veliparib…
Expand
2011
2011
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in…
Patricia M. LoRusso
,
J. Ji
,
+10 authors
R. Parchment
Journal of Clinical Oncology
2011
Corpus ID: 31359404
3000 Background: The nuclear enzyme PARP is essential in recognition and repair of DNA damage. In preclinical models, PARP…
Expand
2010
2010
Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide.
A. Tan
,
D. Gibbon
,
+7 authors
R. DiPaola
2010
Corpus ID: 78629699
3000 Background: ABT-888 is a potent, oral inhibitor of PARP-1 and PARP-2. In preclinical studies, ABT-888 enhances the…
Expand
2009
2009
Phase 0 trials: a platform for drug development?
T. Lancet
The Lancet
2009
Corpus ID: 30939770
2008
2008
Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates
J. Muscal
,
P. Thompson
,
+9 authors
J. Su
Cancer Chemotherapy and Pharmacology
2008
Corpus ID: 25964804
PurposeABT-888 inhibits poly(ADP-ribose) polymerase (PARP) and may enhance the efficacy of chemotherapy and radiation in CNS…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE